CITATION REPORT List of articles citing

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement

DOI: 10.1016/s0140-6736(88)92070-3 Lancet, The, 1988, 1, 1242-5.

Source: https://exaly.com/paper-pdf/19859113/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
238	Manual and automated prothrombin time tests. 1989 , 42, 1117-8	
237	Hemorrhagic complications of long-term anticoagulant therapy. 1989 , 95, 26S-36S	85
236	Optimal Therapeutic Range for Oral Anticoagulants. 1989 , 95, 5S-11S	32
235	Antithrombotic therapy in valvular heart disease. 1989 , 95, 98S-106S	35
234	Long-term use of oral anticoagulants. Current recommendations. 1989 , 86, 50-6, 59, 63-7	
233	Antithrombotic therapy for venous thromboembolic disease. 1989 , 95, 37S-51S	65
232	Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. 1989 , 95, 107S-117S	41
231	Prosthetic valve endocarditis 1976-1987. Antibiotics, anticoagulation, and stroke. <i>Stroke</i> , 1990 , 21, 993-%.7	70
230	Antithrombotic treatment of cerebrovascular disease. 1990 , 3, 781-813	4
229	Side-effects of antithrombotic therapy. 1990 , 3, 815-29	3
228	Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. 1990 , 65, 7C-11C	23
227	Valvular heart disease, infected valves and prosthetic heart valves. 1990 , 65, 29C-31C	10
226	Venous Thromboembolic Disease: Diagnosis and Use of Antithrombotic Therapy. 1990 , 13, VI-23-VI-28	3
225	Platelet Inhibitor Therapy: Agents and Clinical Implications. 1990 , 4, 265-289	6
224	Trial of different intensities of anticoagulation in patients with prosthetic heart valves. 1990 , 322, 428-32	312
223	Research Initiatives in Vascular Surgery*. 1991 , 13, 728-763	
222	Clinical trials: current status and recommendations. 1991 , 13, 761-3	

221	Risk-benefit assessment of anticoagulant therapy. 1991 , 6, 54-69		7
220	Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. 1991 , 42 Suppl 5, 22-38		7
219	Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. 1991 , 101, 427-431		204
218	Low-intensity anticoagulation in mechanical cardiac prosthetic valves. 1991 , 100, 1553-7		33
217	Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. 1991 , 30, 511-8		98
216	Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. <i>Circulation</i> , 1991 , 84, 469-81	6.7	173
215	Oral anticoagulant drugs. 1991 , 324, 1865-75		481
214	Oral Anticoagulants. 1992 , 102, 312S-326S		10
213	Hemorrhagic complications of anticoagulant treatment. 1992 , 102, 352S-363S		103
212	Antithrombotic therapy for venous thromboembolic disease. 1992 , 102, 408S-425S		66
211	Antithrombotic therapy in valvular heart disease. 1992 , 102, 434S-444S		25
210	Oral anticoagulant drugs. 1992 , 326, 68; author reply 68-9		6
209	Non-rheumatic atrial fibrillation: warfarin or aspirin for all?. 1992 , 68, 544-7; discussion 547-8		4
208	Oral anticoagulant therapy. Urgent need for standardization. <i>Circulation</i> , 1992 , 86, 1332-5	5.7	15
207	Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. 1992, 12, 239-49		59
206	Thromboembolism and prosthetic heart valves. 1992 , 27, 69-79, 82-6, 90-6		1
205	Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. 1992 , 102, 445S-455S		88
204	Clinical research and vascular surgery. 1992 , 15, 867-901		5

203	Antithrombotic therapy for lower extremity bypass. 1992 , 15, 873-5	8
202	Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 1992 , 327, 1406-12	1114
201	Considerations for Using Lower Doses of Warfarin. 1992 , 6, 1105-1114	5
200	Atrial fibrillation: epidemiology and the risk and prevention of stroke. 1992 , 15, 1332-46	21
199	Therapeutic ranges for oral anticoagulation in different thromboembolic disorders. 1992 , 64, 52-9	4
198	Therapeutic target values in oral anticoagulationjustification of Dutch policy and a warning against the so-called moderate-intensity regimens. 1992 , 64, 60-5	36
197	Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. 1993 , 95, 315-28	698
196	A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. 1993 , 329, 524-9	454
195	Adverse effects of coumarin anticoagulants. 1993 , 9, 263-71	17
194	Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. 1993 , 329, 696-702	63
193	Stroke prophylaxis: hypertension management and antithrombotic therapy. 1993 , 27, 471-9	5
192	Cardiac Valvular Disease and Stroke. 1993 , 11, 391-398	1
191	Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. 1994 , 107, 1136-1145	101
190	Laboratory Monitoring of Oral Anticoagulant Therapy. 1994 , 14, 813-823	7
189	Preventing Systemic Embolization in Patients with Atrial Fibrillation. 1994 , 12, 495-504	3
188	Oral Anticoagulant Therapy Recommendations. 1994 , 105, 328	
187	Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. <i>Circulation</i> , 1994 , 89, 1469-80	164
186	Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. 1994 , 35, 464-6	105

185	Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. 1994 , 74, 935-9	9
184	Classical anticoagulant therapy for venous thromboembolism. 1994 , 37, 59-70	5
183	Antithrombotic therapy in prosthetic heart valve replacement. 1994 , 127, 400-11	25
182	Atrial fibrillation, stroke, and antithrombotic treatment. 1994 , 127, 961-8	14
181	Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. <i>Lancet, The</i> , 1994 , 343, 886-9	437
180	Coagulation activity and emboli counts in patients with prosthetic cardiac valves. <i>Stroke</i> , 1994 , 25, 1211- 4 .7	35
179	Deep vein thrombosis. Diagnosis and management. 1994 , 78, 685-712	19
178	Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. 1995 , 108, 371S-379S	66
177	Antithrombotic therapy in children. 1995 , 108, 506S-522S	76
176	Hemorrhagic complications of anticoagulant treatment. 1995 , 108, 276S-290S	135
175	Antithrombotic therapy in valvular heart disease. 1995 , 108, 360S-370S	20
174	Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. 1995 , 37, 243-71	53
173	Optimal intensity and monitoring warfarin. 1995 , 75, 39B-42B	30
172	Suppression of plasma-activated factor VII levels by warfarin therapy. 1995 , 15, 241-6	23
171	When bleeding complicates oral anticoagulant therapy. 1995 , 98, 153-168	16
170	Risk Factors for Bleeding during Anticoagulation. 1995 , vmr-6, 53-63	
169	Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. 1995, 36, 483-4	33
168	Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. 1995 , 108, 231S-246S	228

167	Antithrombotic therapy for venous thromboembolic disease. 1995 , 108, 335S-351S	135
166	Anticoagulants in older patients. A safety perspective. 1995 , 6, 45-54	50
165	Drug treatment associated with heart valve replacement. 1995 , 49, 897-911	8
164	Outpatient anticoagulation issues for the primary care physician. 1996 , 80, 475-91	10
163	Cardioembolic stroke. 1996 , 100, 465-74	33
162	The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practice Committee. 1996 , 44, 1112-3	5
161	Prosthetic heart valves. 1996 , 335, 407-16	541
160	Current recommendations for the anticoagulation of patients with atrial fibrillation. 1996 , 39, 1-20	10
159	Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens. 1997 , 101, 85-6, 89-90, 93-4	7
158	The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. 1997 , 336, 153-62	819
157	Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: a 23-year population-based study. 1997 , 72, 1103-10	17
156	Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. 1997 , 40, 205-38	20
155	Low-Dose Vitamin K Therapy in Excessively Anticoagulated Patients: A Dose-Finding Study. 1997 , 4, 289-292	20
154	Bleeding Complications and INR Control of Combined Warfarin and Low-Dose Aspirin Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction. 1998 , 5, 249-255	2
153	Guidelines on oral anticoagulation: third edition. 1998 , 101, 374-87	337
152	Guidelines for antithrombotic therapy in pediatric patients. 1998 , 132, 575-88	113
151	ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). 1998, 32, 1486-588	765
150	Modern management of prosthetic valve anticoagulation. 1998 , 73, 665-80	53

149	Valvular heart disease in pregnancy. A contemporary perspective. 1998 , 16, 573-98, x	13
148	Controversies in Antithrombotic Therapy in Cardiovascular Diseases. 1998 , 4, 11-24	
147	Hemorrhagic complications of anticoagulant treatment. 1998 , 114, 511S-523S	122
146	Antithrombotic therapy for venous thromboembolic disease. 1998 , 114, 561S-578S	170
145	Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. 1998 , 114, 602S-610S	64
144	Antithrombotic therapy in children. 1998 , 114, 748S-769S	73
143	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. 1998, 114, 445S-469S	358
142	Mechanical versus biological isolated aortic valvular replacement after the age of 70: equivalent long-term results. 1998 , 13, 84-9	14
141	Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators. 1999 , 7, 313-8	4
140	Safety of treatment with oral anticoagulants in the elderly. A systematic review. 1999 , 14, 303-12	75
139	CA-1 method, a novel assay for quantification of normal prothrombin using a Ca2+ -dependent prothrombin activator, carinactivase-1. 1999 , 94, 221-6	32
138	Assessment of pericardium in cardiac bioprostheses. A review. 1999 , 13, 351-88	14
137	Intracerebral haemorrhages and oral anticoagulation in the north of Scotland. 2000, 45, 101-4	10
136	The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society. 2000 , 48, 224-7	25
135	Effect of three loading doses of warfarin on the international normalized ratio for dogs. 2000, 61, 48-50	12
134	Perspectives: Oral anticoagulant therapy: current issues. 2000 , 3, 178-182	1
133	Use of oral anticoagulants in older patients. 2000 , 16, 409-35	29
132	Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: fundamental principles and the contribution of platelets and thrombin. 2001 , 141, 1025-37	26

131	Hemorrhagic complications of oral anticoagulant therapy. 2001 , 17, 49-56	23
130	How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage?. 2001 , 119, 478-84	110
129	Antithrombotic therapy in children. 2001 , 119, 344S-370S	206
128	Managing oral anticoagulant therapy. 2001 , 119, 22S-38S	436
127	Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. 2001 , 119, 220S-227S	192
126	The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment. 2001 , 11, 143-9	2
125	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. 2001 , 119, 8S-21S	770
124	Hemorrhagic complications of anticoagulant treatment. 2001 , 119, 108S-121S	415
123	Management of haemorrhagic complications associated with oral anticoagulant treatment. 2002 , 1, 129-36	8
122	Oral anticoagulation and risk of death: a medical record linkage study. 2002 , 325, 1073-5	152
121	Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. 2002 , 35, 413-21	156
120		
	The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline. 2002 , 50, 1439-45; discussion 1446-7	38
119		38 o
119	2002 , 50, 1439-45; discussion 1446-7	
	2002, 50, 1439-45; discussion 1446-7 Manejo de la anticoagulacifi en pacientes con prEesis valvulares. Controversias. 2003, 27, 232-239 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.	0
118	2002, 50, 1439-45; discussion 1446-7 Manejo de la anticoagulacifi en pacientes con pr Esis valvulares. Controversias. 2003, 27, 232-239 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. 2003, 41, 1633-52	0 264
118	2002, 50, 1439-45; discussion 1446-7 Manejo de la anticoagulacifi en pacientes con pr Besis valvulares. Controversias. 2003, 27, 232-239 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. 2003, 41, 1633-52 Anticoagulation and spontaneous retropharyngeal hematoma. 2003, 24, 389-94 American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.	o 264 38

113	. 2003 , 14, 269-275	5
112	Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. 2003 , 14, 269-75	14
111	Managing Complications of Anticoagulant Therapy. 2004 , 17, 327-346	1
110	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 204S-233S	852
109	Management of anticoagulant therapy for patients with prosthetic heart valves or atrial fibrillation. 2004 , 9, 1-9	4
108	Antithrombotic therapy in valvular heart diseasenative and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 457S-482S	267
107	International Normalized Ratios (INR): the first 20 years. 2004 , 2, 849-60	98
106	The multiple faces of the partial thromboplastin time APTT. 2004 , 2, 2254-2256	5
105	Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. 2004 , 24, 600-5	23
104	Anticoagulation management of patients with prosthetic valves. 2004 , 44, 1143-4; author reply 1144-5	
103	Reply. 2004 , 44, 1144-1145	O
102	Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 287S-310S	361
101	Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. 2005 , 59, 582-7	104
100	Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. 2005 , 129, 1024-31	77
99	The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy. 2005 , 3, 1	31
98	Recommendations for the management of patients after heart valve surgery. 2005 , 26, 2463-71	260
97	A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. 2005 , 58, 26-40	37
96	10-year experience with the ATS mechanical valve in the mitral position. 2005 , 79, 1934-8	12

95 Le point sur les prothBes valvulaires. **2006**, 41, 109-123

94	The risk of hemorrhage among patients with warfarin-associated coagulopathy. 2006, 47, 804-8		65
93	ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular		1307
92	heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary? 2006, 48, 598-675		119
91	Early antithrombotic therapy after aortic valve replacement with tissue valves: when the practice diverges from the guidelines. 2006 , 131, 1223		5
90	Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. 2006 , 68, 56-61		59
89	ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists:	16.7	1634
88	endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Effect of oxolamine on anticoagulant effect of warfarin. 2006 , 63, 153-6 moracic surgeons. <i>Circulation</i> , 2006 , 114, e84-231		4
87	ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary. <i>Circulation</i> , 2006 , 114, 450-527	16.7	157
86	Challenges in managing anticoagulant therapy in patients with heart valve prostheses. 2007 , 5, 563-70		
85	Antithrombotic therapy following bioprosthetic aortic valve replacement. 2007, 31, 578-85		22
84	Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue. 2007 , 31, 573-7		12
83	Trouble de l'hfhostase aux urgences. 2007 , 2, 1-23		1
82	Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use?. 2007 , 83, 549-56; discussion 556-7		22
81	Central Nervous System Ischemia. 2007 , 657-683		1
80	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 257S-298S		549
79	2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998		1183
78	2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998	16.7	928
	Guidelines for the Management of Patients With Valvular Heart Disease); endorsed by the Society		

of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*, **2008**, 118, e523-661

77	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 160S-198S	1648
76	Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 593S-629S	199
75	Cerebrovascular Disease. 2009 , 133-214	1
74	Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. <i>Lancet, The</i> , 2009 , 374, 565-76	151
73	Clinical trials in heart valve disease. 2009 , 24, 279-87	2
72	LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. 2010 , 160, 171-8	73
71	Disturbo dell∄mostasi in pronto soccorso. 2010 , 14, 1-22	
70	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e326S-e350S	1175
69	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e44S-e88S	1112
68	Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e576S-e600S	442
67	Central Nervous System Ischemia. 2013 , 669-697	
66	Antithrombotic therapy in patients with heart valve prostheses. 2013 , 21, 27-36	11
65	Should we anticoagulate after bioprosthetic aortic valve replacement?. 2013 , 11, 1649-57	1
64	Solving the mystery of excessive warfarin-induced bleeding: a personal historical perspective. 2014 , 112, 853-6	3
63	2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 16.7 Circulation, 2014, 129, e521-643	1060
62	Spontaneous and non-spontaneous bleeding complications in patients with oral vitamin K antagonist therapy. 2014 , 399, 99-107	1
61	2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 63, e57-185	1905
60	Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. 2014 , 127, 657-663.e2	41

59	2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 148, e1-e132	728
58	New strategies for effective treatment of vitamin K antagonist-associated bleeding. 2015 , 13 Suppl 1, S180-6	10
57	Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. 2015 , CD009658	13
56	Deep Venous Thrombosis. 2015 , 135-149	
55	Anticoagulation for Cardiac Prosthetic Devices: Prosthetic Heart Valves, Left Ventricular Assist Devices, and Septal Closure Devices. 2018 , 253-295	
54	[Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment]. 2018, 43, 26-33	
53	Optimum INR intensity and therapeutic INR control in patients with mechanical heart valve prosthesis on warfarin oral anticoagulation at Dr George Mukhari academic hospital: a three-year retrospective study. 2018 , 60, 192-196	0
52	Fifty years of research on antithrombotic therapy: Achievements and disappointments. 2019 , 70, 1-7	9
51	Cerebrovascular Disease. 2019 , 167-285	1
50	Antiplatelet Drugs in the Management of Cerebral Ischemia. 2019 , 1031-1057	
50 49	Antiplatelet Drugs in the Management of Cerebral Ischemia. 2019 , 1031-1057 Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020 , 383, 2117-2126	67
		67
49	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020 , 383, 2117-2126 A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.	ŕ
49	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020 , 383, 2117-2126 A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 2021 , 231, 128-136	2
49 48 47	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020 , 383, 2117-2126 A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 2021 , 231, 128-136 Eighty years of oral anticoagulation: Learning from history. 2021 , 141, 106918	2
49 48 47 46	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020, 383, 2117-2126 A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 2021, 231, 128-136 Eighty years of oral anticoagulation: Learning from history. 2021, 141, 106918 Antithrombotic Management in Patients with Prosthetic Valves. 246-271 The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes.	1 3
49 48 47 46 45	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 2020, 383, 2117-2126 A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 2021, 231, 128-136 Eighty years of oral anticoagulation: Learning from history. 2021, 141, 106918 Antithrombotic Management in Patients with Prosthetic Valves. 246-271 The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes. 1996, 203-213 The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a	2 1 3

41	The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. 1997 , 19, 7-22		17
40	Preventing warfarin-related bleeding. 2005 , 98, 96-103		7
39	Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. <i>Circulation</i> , 1996 , 93, 2212-45	16.7	439
38	AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. <i>Circulation</i> , 1996 , 94, 2107-12	16.7	141
37	Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. <i>Stroke</i> , 1995 , 26, 1471-7	6.7	357
36	Brain Embolism. 1999 , 35-185		3
35	Acute Thrombolysis in Ischemic Cerebrovascular Disease. <i>Fundamental and Clinical Cardiology</i> , 2009 , 617-650		1
34	Evolution of left atrial thrombus with anticoagulant therapy-follow-up by transesophageal echocardiography. <i>Korean Journal of Internal Medicine</i> , 1995 , 10, 143-5	2.5	2
33	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 266-284	3.1	2
32	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2000 , 2000, 266-284	3.1	
31	Cerebrovascular Disease. 2003 , 117-198		
30	Antithrombotic Approaches in Cerebrovascular Disease. 2006 , 449-466		
29	Hemorrhagic Complications of Anticoagulants in Hospitalized Patients. 291-330		
28	Prevention of Cardioembolic Stroke. 179-203		
27	Antithrombotic strategy in the three first months following bioprosthetic heart valve implantation. <i>Arquivos Brasileiros De Cardiologia</i> , 2013 , 101, 466-72	1.2	4
26	Evaluation of the Bleeding Effects of Antithrombotic Drugs. 1990 , 263-269		
25	Present Status of Anticoagulant Prophylaxis. 1991 , 139-147		
24	Heparin in the prevention and treatment of arterial thromboembolism. <i>Advances in Experimental Medicine and Biology</i> , 1992 , 313, 249-58	3.6	1

23	Pathogenesis and Therapy of Thrombosis in Patients with Congestive Heart Failure. 1994, 687-700	
22	Langzeitantikoagulation bei Herzklappenfehlern. 1994 , 99-118	
21	Erworbene Herzklappenfehler. 1995 , 230-243	
20	CURRENT CONCEPTS OF ANTICOAGULATION THERAPY. Clinics in Chest Medicine, 1995 , 16, 269-280 5.3 6	
19	Postoperative Gerinnungshemmung im Rahmen moderner koronarchirurgischer Operationsverfahren. 1997 , 61-72	
18	Therapie mit oralen Antikoagulanzien. 1999 , 666-678	
17	Erworbene Herzklappenfehler. 1999 , 125-141	
16	Anticoagulant Therapy with Warfarin for Thrombotic Disorders. <i>Handbook of Experimental Pharmacology</i> , 1999 , 353-366	
15	Monitoring Antithrombotic Therapy. <i>Handbook of Experimental Pharmacology</i> , 1999 , 129-155 3.2	
14	[Evaluation of the antithrombotic strategy in low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis]. <i>Archivos De Cardiologia De Mexico</i> , 2018 , 88, 339-346	
13	Monitoring Chronic Oral Anticoagulant Therapy. 1997 , 495-515	
12	Hemorrhagic Complications. 1997, 519-544	
11	Vitamin K Antagonists and Novel Oral Anticoagulant. 2007 , 175-184	
10	Monitoring sodium warfarin therapy using the international normalized ratio. <i>Western Journal of Medicine</i> , 1989 , 151, 544	
9	Long-term anticoagulation. Indications and management. <i>Western Journal of Medicine</i> , 1989 , 151, 414-29	
8	Anticoagulation'sufficient conclusions from insufficient premises'?. Western Journal of Medicine, 1989, 151, 453-4	
7	Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. <i>British Journal of General Practice</i> , 1995 , 45, 153-8	7
6	Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. <i>British Journal of General Practice</i> , 1993 , 43, 152-4	7

CITATION REPORT

5	Antithrombotic therapy in atrial fibrillation. <i>Canadian Family Physician</i> , 1996 , 42, 1341-5	0.9	3
4	Control of anticoagulant and antiplatelet therapy. Managing patients with acute thrombotic disorders. <i>Canadian Family Physician</i> , 1993 , 39, 290-4, 297-300, 303-4	0.9	
3	Adoption and validation of the international normalized ratio for monitoring oral anticoagulant therapy: the situation in 1989. <i>Research in Clinic and Laboratory</i> , 1990 , 20, 75-81		1
2	Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines <i>European Journal of Anaesthesiology</i> , 2022 , 39, 100-132	2.3	5
1	Clinical Studies with Anticoagulants that Have Changed Clinical Practice.		0